| Half-life | ~30 minutes | 6–8 days |
| Dosing Frequency | Multiple daily injections | Weekly to biweekly injections |
| GH Release Pattern | Pulsatile (natural spikes) | Sustained (flat elevation) |
| IGF-1 Levels | Short-lived increase | Elevated for 6–14 days |
| Mimics Natural Secretion | ✅ Yes | ❌ Less physiologic |
| Research Applications | Tissue repair, anti-aging, neuroprotection | GH deficiency, metabolic health |
| Combination Use | Often paired with GHRPs (e.g., Ipamorelin) | Typically used alone |
| Convenience | Less convenient (frequent injections) | Very convenient (long-acting) |
| Safety Considerations | Lower risk of constant IGF-1 | Theoretical risk of tumor growth with prolonged IGF-1 |
| Clinical Trial Evidence | Limited direct studies | Human Phase I data available (Teichman 2006) |
